Clinical effectiveness of cancer screening biomarker tests offered as self-pay health service: a systematic review

Luzak, Agnes; Bühn, Stefanie; Mayer-Zitarosa, Anja; Siebert, Uwe

doi:10.1093/eurpub/ckv227

Cited by 5 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overdiagnosis and resulting overtreatment lead to a reduced quality of life due to bowel, urinary, and sexual complications 28 . Other protein-based and widely used biomarkers in the clinical setting, such as CA-125, have yielded no significant benefits while incurring overdiagnosis and overtreatment 29 . The high specificity of UCOMs for malignancies avoids these shortcomings.…”

Section: Unique To Malignancymentioning

confidence: 99%

The outpost against cancer: universal cancer only markers

Qian,

Zou,

et al. 2023

Cancer Biol Med

View full text Add to dashboard Cite

Cancer is the leading cause of death worldwide. Early detection of cancer can lower the mortality of all types of cancer; however, effective early-detection biomarkers are lacking for most types of cancers. DNA methylation has always been a major target of interest because DNA methylation usually occurs before other detectable genetic changes. While investigating the common features of cancer using a novel guide positioning sequencing for DNA methylation, a series of universal cancer only markers (UCOMs) have emerged as strong candidates for effective and accurate early detection of cancer. While the clinical value of current cancer biomarkers is diminished by low sensitivity and/or low specificity, the unique characteristics of UCOMs ensure clinically meaningful results. Validation of the clinical potential of UCOMs in lung, cervical, endometrial, and urothelial cancers further supports the application of UCOMs in multiple cancer types and various clinical scenarios. In fact, the applications of UCOMs are currently under active investigation with further evaluation in the early detection of cancer, auxiliary diagnosis, treatment efficacy, and recurrence monitoring. The molecular mechanisms by which UCOMs detect cancers are the next important topics to be investigated. The application of UCOMs in real-world scenarios also requires implementation and refinement.

show abstract

Section: Unique To Malignancymentioning

confidence: 99%

The outpost against cancer: universal cancer only markers

Qian,

Zou,

et al. 2023

Cancer Biol Med

View full text Add to dashboard Cite

show abstract

“…Patients better informed will probably question more the effectiveness of treatments, and many procedures which are currently performed will not be accepted by patients. For example, in circumstances when clinicians provide self-pay services to their patients without sound evidence supporting these services (mainly in the case of tests for screening cancer and other diseases) [6].…”

mentioning

confidence: 99%